MBX Biosciences Previews Three Once-Monthly Peptide Candidates Ahead of May 11 Obesity Day
MBX Biosciences announced an April 23 press release confirming its May 11 virtual Obesity Day event, at which the company will formally update investors on its Precision Endocrine Peptide (PEP) platform. The portfolio includes MBX 4291 (Phase 1 GLP-1/GIP co-agonist prodrug designed for once-monthly dosing), an amycretin prodrug with Q2 2026 nomination expected, and a GLP-1/GIP/GCGR triple agonist prodrug with Q3 2026 nomination — all targeting once-monthly administration. Richard DiMarchi and Katherine Saunders will headline the event.